Feline C-Peptide antibody and antigen (recombinant protein)
Diagnostic anti-Feline C-Peptide antibodies pairs and antigen for animal health (animal Cat/Feline type 1 diabetes mellitus) testing in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT
Go to Neurodegenerative diseases diagnostics products collection >>
Product information
Catalog No. | Description | US $ Price (per mg) |
---|---|---|
GMP-FEL-C-Peptide-Ag01 | Recombinant Feline C-Peptide protein | 3090 |
GMP-FEL-C-Peptide-Ab01 | Anti-Feline C-Peptide mouse monoclonal antibody (mAb) | 3090 |
GMP-FEL-C-Peptide-Ab02 | Anti-Feline C-Peptide mouse monoclonal antibody (mAb) | 3090 |
GMP-FEL-C-Peptide-Ab03 | Anti-Feline C-Peptide human monoclonal antibody (mAb) | 3090 |
GMP-FEL-C-Peptide-Ab04 | Anti-Feline C-Peptide human monoclonal antibody (mAb) | 3090 |
Size: 1mg | 10mg | 100mg
Product Description
Cat No. of Products | GMP-FEL-C-Peptide-Ag01 |
Product Name | Recombinant Feline C-Peptide protein |
Target/Biomarker | Canine Acrosomal Vesicle Protein 1 (ACRV1) |
Alias of Target/Biomarker | Canine Acrosomal Vesicle Protein 1 (ACRV1) |
Expression platform | E.coli |
Isotypes | Recombinant Antigen |
Bioactivity validation | Anti-Canine Acrosomal Vesicle Protein 1 antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in ACRV1 level test of animal Cat/Feline with type 1 diabetes mellitus. |
Tag | His |
Products description | Recombinant Feline C-Peptide protein was expressed in E.coli - based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays |
Formulation | Supplied as a 0.2 μM filtered solution of PBS,PH7.4. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Cat No. of Products | GMP-FEL-C-Peptide-Ab01, GMP-FEL-C-Peptide-Ab02 |
Product Name | Anti-Feline C-Peptide mouse monoclonal antibody (mAb) |
Target/Biomarker | Canine Acrosomal Vesicle Protein 1 (ACRV1) |
Alias of Target/Biomarker | Canine Acrosomal Vesicle Protein 1 (ACRV1) |
Expression platform | CHO |
Isotypes | Mouse IgG |
Bioactivity validation | Recombinant Canine Acrosomal Vesicle Protein 1 antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-ACRV1 antibodies in ACRV1 level test of animal Cat/Feline with type 1 diabetes mellitus. |
Tag | mFc |
Products description | Anti-Feline C-Peptide mouse monoclonal antibody (mAb) is a monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-ACRV1 antibodies. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays |
Formulation | Supplied as a 0.2 μM filtered solution of PBS,PH7.4. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Cat No. of Products | GMP-FEL-C-Peptide-Ab03, GMP-FEL-C-Peptide-Ab04 |
Product Name | Anti-Feline C-Peptide human monoclonal antibody (mAb) |
Target/Biomarker | Canine Acrosomal Vesicle Protein 1 (ACRV1) |
Alias of Target/Biomarker | Canine Acrosomal Vesicle Protein 1 (ACRV1) |
Expression platform | CHO |
Isotypes | Human IgG1 |
Bioactivity validation | Recombinant Canine Acrosomal Vesicle Protein 1 antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-ACRV1 antibodies in ACRV1 level test of animal Cat/Feline with type 1 diabetes mellitus. |
Tag | hFc |
Products description | Anti-Feline C-Peptide human monoclonal antibody (mAb) is a monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-ACRV1 antibodies. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays |
Formulation | Supplied as a 0.2 μM filtered solution of PBS,PH7.4. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Validation Data
Click to get more Data / Case study about the product.
Target/Biomarker information
Feline C-Peptide, a remarkable peptide composed of 31 amino acids, is intricately intertwined with the physiological tapestry of cats. It emerges as a critical component of pancreatic function, serving as both a mirror and a marker of endogenous insulin production. C-Peptide is born during the proteolytic cleavage of proinsulin, a precursor to insulin. While insulin takes on the central role in regulating glucose homeostasis, Feline C-Peptide plays a parallel and equally crucial role, co-secreted alongside insulin by the pancreas. Feline C-Peptide follows a pulsatile release pattern into the bloodstream, a pattern that mimics the body's natural insulin secretion. This distinctive feature sets it apart from exogenously administered insulin, which delivers a continuous and uniform dose. As C-Peptide levels rise in response to elevated blood glucose levels, it serves as an invaluable indicator of the pancreas's health and its ability to produce insulin. Beyond its role as a mirror of insulin secretion, Feline C-Peptide plays an essential role in the diagnosis and differentiation of diabetes in cats. This differentiation is not merely a matter of semantics but a pivotal determinant of treatment approaches. Low or undetectable levels of C-Peptide are typically associated with Type 1 diabetes, which results from the autoimmune destruction of pancreatic beta cells, leading to the absence of endogenous insulin production. In contrast, Type 2 diabetes in cats is characterized by varying C-Peptide levels, reflecting a complex interplay of insulin resistance and impaired insulin secretion. The ability to distinguish between these two forms of diabetes guides veterinarians in selecting the most appropriate therapeutic strategies for their feline patients.
About GDU
GDU helps global diagnostic partners in high quality of raw material discovery, development, and application. GDU believes in Protein&antibody Innovation for more reliable diagnostic solutions.
Comments
No comments yet.